Hicks Alexandra, George Michael J, Benjamin Mason, Lacoste Eric, Orr Hilarry C, Melendez Angel, Gardner Donna D'laine
Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, MA, USA.
Patient Informed Development and Health Value Translation, Sanofi, Bridgewater, NJ, USA.
Patient Prefer Adherence. 2025 Aug 9;19:2353-2361. doi: 10.2147/PPA.S522436. eCollection 2025.
For the development of novel and efficacious drugs and improvement of patients' quality of life, the involvement of patient stakeholders in drug development is essential. This study was conducted among patients with asthma to understand their unmet needs with current treatments, and expectations from new treatments.
Sanofi collaborated with the Allergy & Asthma Network (AAN), a US-based patient advocacy group and their patient community. Several virtual patient panels were conducted involving patient advocates and researchers that spanned patient experiences with asthma, treatment options, gaps, needs, and priorities. Additionally, a literature search was conducted using Medline between July 2013 and July 2023.
Based on input gleaned from patients (n=5), their major unmet needs included: management of medication-related side effects, lack of information about correct inhaler techniques, medication costs, misunderstanding of medication dosing schedules, lack of communication between researchers and patients, lack of awareness about patient advocacy organizations and research led programs, and fear of discrimination or having concerns disregarded by healthcare providers. Patients expressed their expectation that new treatments should treat all asthma symptoms, including inflammation, airway constriction, and responsiveness to asthma triggers, all with a single treatment. For patients, an ideal treatment would not need to be taken daily, would be quick-acting, and cost-effective for all patients regardless of their insurance status or coverage. Digital applications that remind patients to take their medications on schedule and monitor asthma triggers, mood, sleep, peak flow recordings, and nutrition could improve patients' treatment adherence, quality of life, and health outcomes would be welcomed.
This study emphasizes the importance of gathering input from patients living with asthma, understanding their unmet needs, and the importance of integrated patient engagement in the development of new therapies for asthma.
为了开发新型有效药物并改善患者生活质量，让患者利益相关者参与药物研发至关重要。本研究针对哮喘患者开展，以了解他们对当前治疗的未满足需求以及对新治疗的期望。
赛诺菲与美国患者倡导组织过敏与哮喘网络（AAN）及其患者群体合作开展研究。组织了多个虚拟患者小组，参与者包括患者倡导者和研究人员，讨论内容涵盖哮喘患者的经历、治疗选择、差距、需求和优先事项。此外，在2013年7月至2023年7月期间使用Medline进行了文献检索。
根据从5名患者收集的意见，他们主要的未满足需求包括：药物相关副作用的管理、缺乏正确吸入器技术的信息、药物成本、对药物给药时间表的误解、研究人员与患者之间缺乏沟通、对患者倡导组织和研究主导项目缺乏认识，以及担心受到医疗服务提供者的歧视或担忧被忽视。患者表示期望新治疗应能治疗所有哮喘症状，包括炎症、气道收缩以及对哮喘触发因素的反应，且只需单一治疗。对患者而言，理想的治疗无需每日服用，起效迅速，且无论患者的保险状况或覆盖范围如何，对所有患者都具有成本效益。能够提醒患者按时服药并监测哮喘触发因素、情绪、睡眠、峰值流量记录和营养状况的数字应用程序，有助于提高患者的治疗依从性、生活质量和健康结果，将会受到欢迎。
本研究强调了收集哮喘患者意见、了解他们未满足需求的重要性，以及患者全面参与哮喘新疗法研发的重要性。
